{"analyses":[{"ciLowerLimit":"74.2","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"90.8","groupDescription":"A binomial exact test was performed to test against the null hypothesis H0: ORR=0.40 using the significant level of 0.025 (1-sided)","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","paramType":"Clopper-Pearson","paramValue":"83.7","statisticalMethod":"Binomial Exact Test"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"72"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"86"}],"units":"Participants"}],"description":"The ORR was assessed in accordance with the 2014 modification of the International Working Group on non-Hodgkin Lymphoma Criteria. The ORR was defined as the percentage of participants achieving a BOR of CR or PR. The BOR was defined as the best response recorded from the start of zanubrutinib until data cut or start of new antineoplastic treatment. Participants with no post-baseline response assessment (due to any reason) were considered non-responders for BOR. For this outcome measure, only investigator-assessed data are analyzed and reported because of the high rate of concordance between the Independent Review Committee and investigator assessments for the primary outcome measure of ORR.","groups":[{"description":"Zanubrutinib (160 mg) administered BID until disease progression, unacceptable toxicity or death, withdrawal of consent, lost to follow up, or study termination by sponsor, which comes first.","id":"OG000","title":"Zanubrutinib"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety Analysis Set: All participants who received any dose of study drug.","reportingStatus":"POSTED","timeFrame":"Up to 3 years and 6 months","title":"ORR As Assessed By The Investigator","type":"SECONDARY","unitOfMeasure":"Participants"}